Sensus Healthcare, Inc. (NASDAQ:SRTS) Given Average Rating of “Hold” by Brokerages

Shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) have received an average recommendation of “Hold” from the five research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $8.00.

Several research firms recently commented on SRTS. Weiss Ratings restated a “sell (d)” rating on shares of Sensus Healthcare in a report on Wednesday, October 8th. HC Wainwright reduced their target price on shares of Sensus Healthcare from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Tuesday, August 12th. Lake Street Capital decreased their price target on shares of Sensus Healthcare from $13.00 to $6.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Zacks Research raised Sensus Healthcare from a “strong sell” rating to a “hold” rating in a research report on Wednesday, October 22nd. Finally, Wall Street Zen downgraded Sensus Healthcare from a “hold” rating to a “sell” rating in a research report on Saturday.

Sensus Healthcare Stock Performance

Shares of SRTS opened at $4.02 on Friday. Sensus Healthcare has a 1 year low of $3.03 and a 1 year high of $9.33. The company has a market capitalization of $66.03 million, a price-to-earnings ratio of -67.00 and a beta of 1.38. The company’s 50 day simple moving average is $3.47 and its 200 day simple moving average is $4.06.

Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.06. Sensus Healthcare had a negative return on equity of 1.58% and a negative net margin of 2.26%.The company had revenue of $6.88 million during the quarter, compared to analysts’ expectations of $6.31 million. Equities analysts expect that Sensus Healthcare will post 0.32 EPS for the current fiscal year.

Insider Transactions at Sensus Healthcare

In related news, CEO Joseph C. Sardano purchased 25,000 shares of Sensus Healthcare stock in a transaction dated Tuesday, November 18th. The shares were acquired at an average price of $4.03 per share, with a total value of $100,750.00. Following the completion of the transaction, the chief executive officer owned 1,200,293 shares of the company’s stock, valued at approximately $4,837,180.79. This trade represents a 2.13% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Eric Sachetta acquired 7,000 shares of the firm’s stock in a transaction on Friday, November 21st. The stock was acquired at an average cost of $3.93 per share, with a total value of $27,510.00. Following the acquisition, the director owned 140,113 shares of the company’s stock, valued at $550,644.09. This trade represents a 5.26% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have bought 36,500 shares of company stock worth $147,570. Corporate insiders own 8.90% of the company’s stock.

Institutional Trading of Sensus Healthcare

Several hedge funds have recently made changes to their positions in SRTS. American Century Companies Inc. boosted its position in Sensus Healthcare by 12.7% during the 1st quarter. American Century Companies Inc. now owns 22,440 shares of the company’s stock valued at $106,000 after purchasing an additional 2,520 shares during the period. Geode Capital Management LLC lifted its stake in Sensus Healthcare by 2.5% in the second quarter. Geode Capital Management LLC now owns 153,917 shares of the company’s stock valued at $730,000 after buying an additional 3,766 shares during the last quarter. Sachetta LLC boosted its holdings in shares of Sensus Healthcare by 3.0% during the second quarter. Sachetta LLC now owns 128,675 shares of the company’s stock valued at $610,000 after acquiring an additional 3,788 shares during the period. IFP Advisors Inc grew its position in shares of Sensus Healthcare by 37.2% during the first quarter. IFP Advisors Inc now owns 18,800 shares of the company’s stock worth $89,000 after acquiring an additional 5,100 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in shares of Sensus Healthcare by 3.9% in the 1st quarter. Bank of New York Mellon Corp now owns 141,971 shares of the company’s stock worth $672,000 after acquiring an additional 5,289 shares during the period. Institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.